Terms: = Endocrine gland cancer AND CEACAM5, CEA AND Clinical Outcome
11 results:
1. The expression and clinical prognostic value of protein phosphatase 1 catalytic subunit beta in pancreatic cancer.
Hu L; Xu H; Wang X; Wu B; Chen F; Chen W; Gao Y; Zhong Z
Bioengineered; 2021 Dec; 12(1):2763-2778. PubMed ID: 34125004
[TBL] [Abstract] [Full Text] [Related]
2. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract] [Full Text] [Related]
3. Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits.
Pelizzo MR; Torresan F; Da Roit A; Merante Boschin I; Chondrogiannis S; Rampin L; Colletti PM; Vinjamury S; Perkins AJ; Rubello D
Rev Esp Med Nucl Imagen Mol; 2015; 34(6):378-82. PubMed ID: 26420439
[TBL] [Abstract] [Full Text] [Related]
4. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S; Sasajima Y; Kasamatsu T; Oda-Otomo R; Okada S; Ishikawa M; Ikeda S; Kato T; Tsuda H
Pathol Oncol Res; 2015 Apr; 21(2):487-94. PubMed ID: 25370301
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma.
Distler M; Rückert F; Hunger M; Kersting S; Pilarsky C; Saeger HD; Grützmann R
BMC Surg; 2013 Apr; 13():12. PubMed ID: 23607915
[TBL] [Abstract] [Full Text] [Related]
6. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
[TBL] [Abstract] [Full Text] [Related]
7. Development of a multimarker assay for early detection of ovarian cancer.
Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
[TBL] [Abstract] [Full Text] [Related]
8. Can the early reduction of tumour markers predict outcome in surgically treated sporadic medullary thyroid carcinoma?
Bümming P; Ahlman H; Nilsson B; Nilsson O; Wängberg B; Jansson S
Langenbecks Arch Surg; 2008 Sep; 393(5):699-703. PubMed ID: 18626656
[TBL] [Abstract] [Full Text] [Related]
9. Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis.
Ohike N; Morohoshi T
Endocr Pathol; 2005; 16(1):33-40. PubMed ID: 16000844
[TBL] [Abstract] [Full Text] [Related]
10. [Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Tendo M; Nakata B; Nishino H; Inoue M; Kosaka K; Amano R; Yamada N; Hirakawa K
Gan To Kagaku Ryoho; 2005 Jun; 32(6):795-8. PubMed ID: 15984518
[TBL] [Abstract] [Full Text] [Related]
11. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Stein R; Goldenberg DM
Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
[TBL] [Abstract] [Full Text] [Related]
